LNTH Stock Surges 13% With A 8-day Spree On Strategic Divestiture
Lantheus (LNTH) – a developer of diagnostic and therapeutic imaging agents – hit a 8-day winning streak, with cumulative gains over this period amounting to 13%. The company’s market cap has surged by about $551 Mil over the last 8 days and currently stands at $4.9 Bil.
The stock has YTD (year-to-date) return of 9.8% compared to 0.5% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] Strategic Divestiture and Analyst Confidence
- Beyond Price Action: Does DG Offer Genuine Diversification?
- Kyndryl Stock: Strong Cash Flow Poised for a Re-Rating?
- S&P Global Stock Pays Out $29 Bil – Investors Take Note
- General Motors Stock Hands $29 Bil Back – Worth a Look?
- Coinbase Global Stock Testing Price Floor – Buy Now?
- Intuit Stock Near Crucial Support – Buy Signal?
- Completed sale of SPECT business to focus on high-growth PET radiodiagnostics
- TD Cowen updated its financial model with a Buy rating and $75 price target
- Impact: Sustained Upward Price Movement, Increased Investor Confidence
[2] Technical Breakout
- Price crossed above 50-day moving average on Feb 10, 2026
- 50-day moving average crossed above 200-day moving average on Feb 13, 2026
- Impact: Shift From Downward to Upward Trend, Long-term Bullish Signal
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in LNTH stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (For details, see Buy or Sell LNTH).
But here is the real interesting point.
You are reading about this 13% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for LNTH stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | LNTH | S&P 500 |
|---|---|---|
| 1D | 2.5% | 0.6% |
| 8D (Current Streak) | 12.6% | 1.2% |
| 1M (21D) | 13.7% | -0.8% |
| 3M (63D) | 37.8% | 2.2% |
| YTD 2026 | 9.8% | 0.5% |
| 2025 | -25.6% | 16.4% |
| 2024 | 44.3% | 23.3% |
| 2023 | 21.7% | 24.2% |
However, big gains can follow sharp reversals – but how has LNTH behaved after prior drops? See LNTH Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 99 S&P constituents with 3 days or more of consecutive gains and 17 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 82 | 10 |
| 4D | 11 | 5 |
| 5D | 3 | 2 |
| 6D | 1 | 0 |
| 7D or more | 2 | 0 |
| Total >=3 D | 99 | 17 |
Key Financials for Lantheus (LNTH)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $1.3 Bil | $1.5 Bil |
| Operating Income | $364.6 Mil | $448.6 Mil |
| Net Income | $326.7 Mil | $312.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $378.0 Mil | $384.0 Mil |
| Operating Income | $88.0 Mil | $43.6 Mil |
| Net Income | $78.8 Mil | $27.8 Mil |
While LNTH stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.